Your browser doesn't support javascript.
loading
A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors.
Cressman, Alex M; Macdonald, Erin M; Fernandes, Kimberly A; Gomes, Tara; Paterson, J Michael; Mamdani, Muhammad M; Juurlink, David N.
Afiliación
  • Cressman AM; The Institute for Clinical Evaluative Sciences, Toronto, Ontario.
  • Macdonald EM; Department of Medicine, Faculty of Medicine, University of Toronto, Ontario.
  • Fernandes KA; The Institute for Clinical Evaluative Sciences, Toronto, Ontario.
  • Gomes T; The Institute for Clinical Evaluative Sciences, Toronto, Ontario.
  • Paterson JM; The Institute for Clinical Evaluative Sciences, Toronto, Ontario.
  • Mamdani MM; Institute of Health Policy, Management and Evaluation, Toronto, Ontario.
  • Juurlink DN; The Leslie Dan Faculty of Pharmacy, Toronto, Ontario.
Br J Clin Pharmacol ; 80(4): 662-9, 2015 Oct.
Article en En | MEDLINE | ID: mdl-25980448
AIMS: Clopidogrel and angiotensin converting enzyme (ACE) inhibitors are commonly co-prescribed drugs. Clopidogrel inhibits carboxylesterase 1 (CES1), the enzyme responsible for converting prodrug ACE inhibitors (such as ramipril and perindopril) to their active metabolites. The clinical implications of this potential drug interaction are unknown. The clinical consequences of the potential drug interaction between clopidogrel and prodrug ACE inhibitors were examined. METHODS: We conducted a nested case-control study of Ontarians aged 66 years and older treated with clopidogrel between September 1 2003 and March 31 2013 following acute myocardial infarction. Cases were subjects who died or were hospitalized for reinfarction or heart failure in the subsequent year, and each was matched with up to four controls. The primary outcome was a composite of reinfarction, heart failure or death. The primary analysis examined whether use of the prodrug ACE inhibitors ramipril or perindopril was more common among cases than use of lisinopril, an active ACE inhibitor. RESULTS: Among 45 918 patients treated with clopidogrel following myocardial infarction, we identified 4203 cases and 14 964 controls. After adjustment, we found no association between the composite outcome and use of perindopril (adjusted odds ratio (aOR) 0.94, 95% confidence interval (CI) 0.76, 1.16) or ramipril (aOR 0.97, 95% CI 0.80, 1.18), relative to lisinopril. Secondary analyses of each element of the composite outcome yielded similar findings. CONCLUSIONS: Following myocardial infarction, use of clopidogrel with ACE inhibitors activated by CES1 is not associated with an increased risk of adverse cardiovascular outcomes relative to lisinopril. These findings suggest that the recently described drug interaction between clopidogrel and prodrug ACE inhibitors is of little clinical relevance.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ticlopidina / Inhibidores de la Enzima Convertidora de Angiotensina / Ramipril / Lisinopril / Perindopril Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: Br J Clin Pharmacol Año: 2015 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ticlopidina / Inhibidores de la Enzima Convertidora de Angiotensina / Ramipril / Lisinopril / Perindopril Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: Br J Clin Pharmacol Año: 2015 Tipo del documento: Article Pais de publicación: Reino Unido